0
0
A recent study by researchers from Brigham and Women’s Hospital and Massachusetts General Hospital in the US has identified a potential link between the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a medication for Type 2 diabetes, and a reduced risk of developing kidney stones. The findings, reported in JAMA Internal Medicine, indicate that individuals with Type 2 diabetes who took SGLT2 inhibitors had a 30% lower risk of kidney stones compared to those using other diabetes medications such as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.
The research involved analyzing data from three nationwide databases in the US, covering patients with Type 2 diabetes seen in routine clinical practice. The study included information from 716,406 adults with Type 2 diabetes who initiated treatment with either SGLT2 inhibitors, GLP1 receptor agonists, or DPP4 inhibitors.
The results demonstrated a consistent pattern across various demographic factors, such as sex, race/ethnicity, history of chronic kidney disease, and obesity. Patients who started taking SGLT2 inhibitors exhibited a 30% lower risk of developing kidney stones than those using GLP1 agonists and a 25% lower risk than those using DPP4 inhibitors.
“These findings could help inform clinical decision-making for patients with diabetes who are at risk for developing kidney stones,” said Julie Paik, the corresponding author from the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. The study suggests a potential dual benefit for individuals with Type 2 diabetes, addressing both the condition and reducing the risk of kidney stones.
